Dillip obtained his Master’s in Pharmaceutical & Pharmaceutical Technology from LM college of Pharmacy, Ahmedabad, Gujarat India. He has about 15 plus years of work experience in Research & Development, Business Development and Manufacturing Plant operations.
He worked in the Innovation &Generic Pharmaceutical industry for over 15 years, handling product and process development activities. During this time, he was responsible for developing several solid and liquid dosage form products and got several ANDAs approved by the US FDA, MHRA, Health Canada, TGA etc. After leading formulation Development teams in companies like ZydusCadila, Mylan Laboratories Ranbaxy Research Laboratory, India & Dr.Reddy’s Laboratories he moved to Aizant for setting up In house products portfolio. Under his visionary leadership Aizant filed & got approval for multiple complex generic and NCE-1 products.After his successful stint at Aizant, he took the responsibility asPresident R&D and Operations at Optimus pharma where he played important role in reforming the business model, under his visionary and vibrant leadership Optimus pharma observed the peaks of growth. Optimus was amongst few first Indian companies to launch & get approval for anti-corona Favipiravir Tablets.
He has rich experience that encompasses activities from formulation development to product approvals for the US, Europe and other regulated markets. He managed entire product development program from molecule selection, development strategy, risk assessment analysis, infringement analysis and regulatory filings of generic products. He has several patents, at various stages, to his credit. He was exposed to generic product development from Para I to Para IV filings and he has substantial experience in filing NDAs as well.
Dillip has hands on experience in developing formulations of Antidepressant, Anti-allergic, Antiviral, Anti-diabetic and Cardiovascular drugs. His research projects included development of Para IV / modified release / sustained release generic formulations based on matrix / pelletization / osmotic delivery technologies for oral solid dosage forms. He has several publications and research papers to his credit.
He joined Finoso Pharma in Aug 2020 and has been running the company successfully ever since as its Director& CTO.
